For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
As of close of business last night, Myriad Genetics, Inc.’s stock clocked out at $18.64, down -1.48% from its previous closing price of $18.92. In other words, the price has decreased by -$1.48 from its previous closing price. On the day, 0.55 million shares were traded. MYGN stock price reached its highest trading level at $19.31 during the session, while it also had its lowest trading level at $18.6.
Ratios:
To gain a deeper understanding of MYGN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 1.87 and its Current Ratio is at 2.01. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.17.
On December 19, 2023, Wells Fargo started tracking the stock assigning a Equal Weight rating and target price of $20.
On December 14, 2023, Guggenheim started tracking the stock assigning a Buy rating and target price of $23.Guggenheim initiated its Buy rating on December 14, 2023, with a $23 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 01 ’23 when Riggsbee Richard Bryan sold 30,000 shares for $19.09 per share. The transaction valued at 572,835 led to the insider holds 291,812 shares of the business.
Riggsbee Richard Bryan sold 30,000 shares of MYGN for $470,622 on Nov 01 ’23. The Chief Financial Officer now owns 321,812 shares after completing the transaction at $15.69 per share. On Jun 02 ’23, another insider, SPIEGELMAN DANIEL K, who serves as the Director of the company, sold 8,638 shares for $23.01 each. As a result, the insider received 198,760 and left with 40,493 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, MYGN now has a Market Capitalization of 1675267968 and an Enterprise Value of 1686467840. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.22 while its Price-to-Book (P/B) ratio in mrq is 2.14. Its current Enterprise Value per Revenue stands at 2.239 whereas that against EBITDA is -20.393.
Stock Price History:
The Beta on a monthly basis for MYGN is 1.98, which has changed by -0.14808047 over the last 52 weeks, in comparison to a change of 0.2160933 over the same period for the S&P500. Over the past 52 weeks, MYGN has reached a high of $24.21, while it has fallen to a 52-week low of $13.82. The 50-Day Moving Average of the stock is -14.27%, while the 200-Day Moving Average is calculated to be -3.55%.
Shares Statistics:
It appears that MYGN traded 618.05K shares on average per day over the past three months and 530350 shares per day over the past ten days. A total of 89.90M shares are outstanding, with a floating share count of 86.02M. Insiders hold about 4.29% of the company’s shares, while institutions hold 101.45% stake in the company. Shares short for MYGN as of 1711584000 were 5665134 with a Short Ratio of 9.17, compared to 1709164800 on 3999874. Therefore, it implies a Short% of Shares Outstanding of 5665134 and a Short% of Float of 8.709999999999999.
